SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Acquired by Assetmark Inc.

Assetmark Inc. increased its stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 13.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 46,020 shares of the company’s stock after purchasing an additional 5,546 shares during the period. Assetmark Inc. owned 0.06% of SpringWorks Therapeutics worth $1,474,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. SG Americas Securities LLC lifted its position in shares of SpringWorks Therapeutics by 8.3% in the first quarter. SG Americas Securities LLC now owns 4,673 shares of the company’s stock valued at $230,000 after acquiring an additional 358 shares in the last quarter. Sei Investments Co. boosted its stake in SpringWorks Therapeutics by 79.5% during the 1st quarter. Sei Investments Co. now owns 48,662 shares of the company’s stock worth $2,395,000 after purchasing an additional 21,558 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of SpringWorks Therapeutics by 49.0% during the first quarter. Russell Investments Group Ltd. now owns 170,047 shares of the company’s stock worth $8,370,000 after buying an additional 55,893 shares in the last quarter. ProShare Advisors LLC raised its position in shares of SpringWorks Therapeutics by 15.7% in the first quarter. ProShare Advisors LLC now owns 17,473 shares of the company’s stock valued at $860,000 after buying an additional 2,368 shares during the last quarter. Finally, Orion Portfolio Solutions LLC lifted its stake in shares of SpringWorks Therapeutics by 32.7% in the first quarter. Orion Portfolio Solutions LLC now owns 28,878 shares of the company’s stock worth $1,421,000 after buying an additional 7,124 shares in the last quarter.

SpringWorks Therapeutics Price Performance

Shares of NASDAQ SWTX opened at $36.55 on Friday. SpringWorks Therapeutics, Inc. has a 1 year low of $19.61 and a 1 year high of $53.92. The company has a market capitalization of $2.71 billion, a P/E ratio of -8.95 and a beta of 0.79. The company has a 50 day simple moving average of $32.82 and a 200-day simple moving average of $37.21.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.04. The company had revenue of $49.10 million for the quarter, compared to the consensus estimate of $53.28 million. SpringWorks Therapeutics had a negative return on equity of 47.16% and a negative net margin of 203.09%. The company’s revenue for the quarter was up 4810.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.27) earnings per share. As a group, research analysts expect that SpringWorks Therapeutics, Inc. will post -3.36 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on SWTX shares. HC Wainwright dropped their price objective on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a research note on Tuesday. JPMorgan Chase & Co. upped their price target on SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Finally, Wedbush reiterated an “outperform” rating and set a $77.00 price objective on shares of SpringWorks Therapeutics in a research report on Thursday, November 7th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $68.17.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.